Introduction: Urothelial papilloma should be distinguished from low-grade urothelial carcinoma. We report our experience with glucose transporter-1 (Glut-1) expression in urothelial papilloma. Materials and Methods: From January 1987 to December 2002, 32 patients with papilloma were diagnosed. Glut-1 protein expression was studied in 32 cases of papilloma and 30 cases of carcinoma. Clinical information was obtained by chart review. Results: Mean age was 54.7 years, and the solitary lesion was 78.1%. No case of bladder papilloma expressed Glut-1 protein even in cases of recurrent papilloma. However, 67% of urothelial carcinoma specimens were stained for Glut-1 protein. Two patients developed recurrent papilloma (6.2%), 1 of whom (3.1%) developed an urothelial carcinoma 4 years after diagnosis of papilloma. Conclusions: The study showed that papilloma does not express the Glut-1 protein in contrast to urothelial carcinoma. This distinctive expression pattern of Glut-1 will possibly contribute to differentiate urothelial papilloma from low-grade urothelial carcinoma.

Keywords:
Urothelial papilloma, Bladder, Glucose transporter type-1
This content is only available via PDF.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.